ClinicalTrials.gg
RecruitingNCT06030843TREAT-CRSUpdated Jun 16, 2026

The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1

A Phase 2/3 interventional study of Empagliflozin 10 MG and Placebo in Empagliflozin in Cardiorenal Syndrome Type 1, sponsored by Chulalongkorn University. Recruiting at 1 site in Thailand. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-16.

Sponsored by Chulalongkorn University · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Effects of Empagliflozin compared with placebo in cardiorenal syndrome type 1, evaluated by MAKE30.

02

Conditions studied

  • Empagliflozin in Cardiorenal Syndrome Type 1

Browse trials for

Keywords

  • Empagliflozin
  • SGLT2i
  • Cardiorenal syndrome
  • ADHF
  • AKI
03

In context

Cardio-Renal Syndrome

85 studies on the registry are indexed under Cardio-Renal Syndrome; 20 are open to participants now.

This study's planned enrollment of 200 is above the median of 50 across 55 interventional studies indexed under Cardio-Renal Syndrome.

Browse Cardio-Renal Syndrome studies →

Lead sponsor

Chulalongkorn University is the lead sponsor of 323 studies on the registry; 67 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or more
  • Hospitalized for the primary diagnosis of acute denovo or decompensated chronic heart regardless of
  • AKI KDIGO any stage or urine NGAL ≥ 150 ng/mL
  • Must be able to be enrolled into the trial ≤ 12 hours of diagnosis of AKI or elevated urine NGAL

Exclusion criteria

Exclusion criteria

  • Denied to participate in the study
  • Cardiogenic shock or unstable hemodynamic (systolic blood pressure of at least 100 mmHg or required inotropic support within last 24 hours)
  • Cardiac mechanical support (i.e. extracorporeal membrane oxygenation and intra-aortic balloon pump)
  • Acute coronary syndrome
  • Diagnosed with cause of AKI other than cardiorenal syndrome (eg. sepsis, nephrotoxic, dehydration)
  • Anuria or requiring dialysis or expected to required dialysis within 24 hr
  • Baseline ≤ 20 ml/min/1.73m2 with or without dialysis initiated
  • Heart or kidney transplanted
  • Previously received any SGLT2i in the last 3 months before admission
  • Allergic to any SGLT2i
  • Type 1 diabetes mellitus
  • History of ketoacidosis, including diabetic ketoacidosis
  • Pregnancy
  • Comorbid conditions with an expected survival of less than 1 months such as end-stage liver or heart disease, or uncurable
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Empagliflozin

    Empagliflozin 10 mg po OD

    Drug: Empagliflozin 10 MG

  • Placebo comparator
    Placebo

    Matching placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. MAKE30

    The composite outcome of death, new dialysis, and sustained loss of kidney function (which was defined as a 25% or greater decline in eGFR from baseline) assess at 30 days following randomization

    Time frame: 30 days

Secondary outcomes

  1. In-hospital mortality rate

    In-hospital mortality rate

    Time frame: During admission

  2. 30-days mortality rate

    30-days mortality rate

    Time frame: 30 days

  3. Initiation of Renal Replacement therapy

    Initiation of Renal Replacement therapy

    Time frame: 30 days

  4. Sustained loss of kidney function defined as a 25% or greater decline in eGFR at 30 days following randomisation compared to baseline eGFR

    Sustained loss of kidney function defined as a 25% or greater decline in eGFR at 30 days following randomisation compared to baseline eGFR

    Time frame: 30 days

  5. Recurrent heart failure

    Recurrent heart failure required hospital administration

    Time frame: 30 days

  6. Vasoactive drug

    Vasoactive drug use

    Time frame: 30 days

  7. Mechanical ventilation

    Mechanical ventilation use

    Time frame: 30 days

  8. Ventricular tachycardia or ventricular fibrillation

    Ventricular tachycardia or ventricular fibrillation

    Time frame: 30 days

  9. Resuscitation following a cardiac arrest

    Resuscitation following a cardiac arrest

    Time frame: 30 days

  10. Reduction of prespecified renal biomarkers

    Reduction of prespecified renal biomarkers

    Time frame: 30 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2025 (actual). Primary completion is estimated for Nov 2026, 20 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2023
First posted
Sep 11, 2023
StartActual
Mar 1, 2025
Primary completionEst.
Nov 30, 2026
CompletionEst.
Dec 31, 2026
Last update
Jun 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06030843
Responsible party
Nattachai Srisawat ,M.D. (Professor, Chulalongkorn University) — Principal investigator
First posted
Sep 11, 2023
Start date
Mar 1, 2025
Primary completion
Nov 30, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jun 16, 2026

Study contacts

Sasipha Tachaboon
Contact
sasipha.t@chulahospital.org
6622564000 ext. 73305
Nattachai Srisawat
principal investigator · Chulalongkorn University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Empagliflozin

Start the discussion